APH — Alliance Pharma Share Price
Last trade - 00:00- £340.20m
- £447.06m
- £163.21m
- 64
- 53
- 29
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.52 | ||
| PEG Ratio (f) | 0.61 | ||
| EPS Growth (f) | 23.36% | ||
| Dividend Yield (f) | 2.9% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.15 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 10.65 | ||
| Price to Sales | 2.08 | ||
| EV to EBITDA | 14.5 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.03% | ||
| Return on Equity | 4.22% | ||
| Operating Margin | 12.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 101.64 | 118.21 | 135.64 | 129.8 | 163.21 | 171.22 | 189.57 | 10.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +28.93 | -2.03 | +7.34 | -17.09 | -41.99 | +78.04 | +23.36 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alliance Pharma plc is a United Kingdom-based holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's asset portfolio focused on two areas: Consumer Healthcare brands and Prescription Medicines. It holds marketing rights to approximately 80 consumer healthcare brands and Prescription Medicines, which are sold worldwide in approximately 100 countries. Its products include Aloclair, Alliance Calcium Syrup, Aiweidi, Biodermatin, Biotaches, Changmin, Decapional, Dermachronic, Dermacide, Dervida, Effadiane, Fazol, Flammacerium, Gen-Ongles, Irenat, Malunjunshe, MolluDab, Neostigmine and Nu-Seals and other. The Company’s brands also include Kelo-Cote, Nizoral, Amberen, MacuShield, Vamousse, Hydromol, Forceval, Ashton & Parsons, Anbesol, and Aloclair. Its geographical area includes Europe, Middle East and Africa (EMEA), Asia Pacific and China (APAC) and Americas (AMER).
Directors
- David Cook NEC (53)
- Peter Butterfield CEO
- Andrew Franklin CFO
- Stephen Kidner COO
- Janice Timberlake CHO
- Alex Duggan OTH
- Dan Thomas OTH
- Chris Chrysanthou SEC
- Jo Couilliard NID
- Richard Jones NID
- Kristof Neirynck NID
- Last Annual
- December 31st, 2021
- Last Interim
- June 30th, 2022
- Incorporated
- June 26th, 2001
- Public Since
- November 22nd, 2001
- No. of Employees
- 250
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 539,995,086
- Address
- Avonbridge House, Bath Road, CHIPPENHAM, SN15 2BB
- Web
- https://www.alliancepharmaceuticals.com/
- Phone
- +44 1249466966
- Auditors
- KPMG LLP
Latest News for APH
Upcoming Events for APH
Full Year 2022 Alliance Pharma PLC Earnings Release
Similar to APH
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Benchmark Holdings
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
Celadon Pharmaceuticals
London Stock Exchange
FAQ
As of Today at 12:00 UTC, shares in Alliance Pharma are trading at 63.00p. This share price information is delayed by 15 minutes.
Shares in Alliance Pharma last closed at 63.00p and the price had moved by -41.88% over the past 365 days. In terms of relative price strength the Alliance Pharma share price has underperformed the FTSE All Share Index by -42.2% over the past year.
The overall consensus recommendation for Alliance Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Alliance Pharma dividend yield is 2.73% based on the trailing twelve month period.
Last year, Alliance Pharma paid a total dividend of £0.02, and it currently has a trailing dividend yield of 2.73%. We do not have any data on when Alliance Pharma is to next pay dividends.
We do not have data on when Alliance Pharma is to next pay dividends. The historic dividend yield on Alliance Pharma shares is currently 2.73%.
To buy shares in Alliance Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 63.00p, shares in Alliance Pharma had a market capitalisation of £340.20m.
Here are the trading details for Alliance Pharma:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: APH
Based on an overall assessment of its quality, value and momentum Alliance Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Alliance Pharma is 96.67p. That is 53.44% above the last closing price of 63.00p.
Analysts covering Alliance Pharma currently have a consensus Earnings Per Share (EPS) forecast of £0.04 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alliance Pharma. Over the past six months, its share price has underperformed the FTSE All Share Index by -35.86%.
As of the last closing price of 63.00p, shares in Alliance Pharma were trading -23.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alliance Pharma PE ratio based on its reported earnings over the past 12 months is 11.52. The shares last closed at 63.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alliance Pharma's management team is headed by:
- David Cook - NEC
- Peter Butterfield - CEO
- Andrew Franklin - CFO
- Stephen Kidner - COO
- Janice Timberlake - CHO
- Alex Duggan - OTH
- Dan Thomas - OTH
- Chris Chrysanthou - SEC
- Jo Couilliard - NID
- Richard Jones - NID
- Kristof Neirynck - NID